Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Secretagogin expression delineates functionally-specialized populations of striatal parvalbumin-containing interneurons.

eLife | 2016

Corticostriatal afferents can engage parvalbumin-expressing (PV+) interneurons to rapidly curtail the activity of striatal projection neurons (SPNs), thus shaping striatal output. Schemes of basal ganglia circuit dynamics generally consider striatal PV+ interneurons to be homogenous, despite considerable heterogeneity in both form and function. We demonstrate that the selective co-expression of another calcium-binding protein, secretagogin (Scgn), separates PV+ interneurons in rat and primate striatum into two topographically-, physiologically- and structurally-distinct cell populations. In rats, these two interneuron populations differed in their firing rates, patterns and relationships with cortical oscillations in vivo. Moreover, the axons of identified PV+/Scgn+ interneurons preferentially targeted the somata of SPNs of the so-called 'direct pathway', whereas PV+/Scgn- interneurons preferentially targeted 'indirect pathway' SPNs. These two populations of interneurons could therefore provide a substrate through which either of the striatal output pathways can be rapidly and selectively inhibited to subsequently mediate the expression of behavioral routines.

Pubmed ID: 27669410 RIS Download

Associated grants

  • Agency: Medical Research Council, United Kingdom
    Id: MC_UU_12024/1
  • Agency: NIH HHS, United States
    Id: P51 OD011132
  • Agency: Wellcome Trust, United Kingdom
    Id: 101821
  • Agency: Medical Research Council, United Kingdom
    Id: MC_UU_12024/2
  • Agency: Medical Research Council, United Kingdom
    Id: MC_UU_12020/5
  • Agency: Parkinson's UK, United Kingdom
    Id: J-0901
  • Agency: Wellcome Trust, United Kingdom
    Id: 109030/Z/15/Z

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


SD (tool)

RRID:RGD_70508

Rattus norvegicus with name SD from RGD.

View all literature mentions

SD (tool)

RRID:RGD_70508

Rattus norvegicus with name SD from RGD.

View all literature mentions

C57BL/6J (tool)

RRID:IMSR_JAX:000664

Mus musculus with name C57BL/6J from IMSR.

View all literature mentions

SCGN antibody (antibody)

RRID:AB_10864618

This polyclonal targets SCGN antibody

View all literature mentions

Anti-PENK (antibody)

RRID:AB_902714

This polyclonal targets PENK

View all literature mentions

Neuropeptide Y Antibody (antibody)

RRID:AB_2307354

This polyclonal targets Neuropeptide Y

View all literature mentions

Anti-NeuN (antibody)

RRID:AB_2298772

This monoclonal targets NeuN

View all literature mentions

Anti-Gephyrin (antibody)

RRID:AB_2232546

This monoclonal targets Gephyrin

View all literature mentions

DARPP-32 (N-19) (antibody)

RRID:AB_639002

This polyclonal targets PPP1R1B

View all literature mentions

Anti-Choline Acetyltransferase Antibody (antibody)

RRID:AB_2079751

This polyclonal targets Choline Acetyltransferase

View all literature mentions